Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

Phase 2

Completed

• Conditions: Chronic Hepatitis C
• Interventions: Biological: IC41

• Registration Number: NCT00602784
• Lead Sponsor: Valneva Austria GmbH

Brief Summary

The objectives are

1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine.

2. to document virological (HCV-RNA) and biochemical (ALT) responses following immunization with HCV antigen peptide vaccine with polyarginine.

3. to assess the safety of immunization with HCV antigen peptide vaccine with polyarginine.

Detailed Description

This is a double blind, randomized, parallel group, controlled, multicenter phase II study.

60 patients will be enrolled and assigned to one of the 5 dose or control groups. Each study group will include 8 patients.

Each patient will receive a total of 6 injections according to the dose of the assigned study group. The injections will be administered subcutaneously in the upper arm once every four weeks for 5 months, i.e. at days 1, 29, 57, 85, 113 and 141.

The volume of each injection will be 0.5 ml in all groups.

Study Timeline

• Study Start: 2002-11
• Primary Completion: 2004-05
• Study Completion: 2004-09
• Study First Submitted: 2008-01-04
• Study First Submitted QC: 2008-01-15
• Study First Posted: 2008-01-28
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-18
• Last Update Posted: 2012-10-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Diagnosis of chronic hepatitis C
• Non-response to or relapse from primary standard HCV therapy
• HLA A2 positive
• HCV-RNA positive
• HCV antibodies positive
• Liver biopsy within 30 months prior to inclusion
• Hematology and biochemistry laboratory results within the limits normally expected for the patient population (liver values maximal 5 times the upper limit of normal)
• Male and female
• From 18 to 65 years
• Written informed consent obtained prior to study entry

Exclusion Criteria

• Any degree of liver cirrhosis or fibrosis of Ishak score ≥ 4 (for grading table, see APPENDIX 2: The Ishak Modified Hepatic Activity Index (HAI))
• Any liver disease other than hepatitis C
• History of autoimmune disease
• Immunodeficiency including post-organ-transplantation
• HIV infection
• Immunosuppressive therapy
• Any acute infections within 4 weeks prior to inclusion
• History of severe hypersensitivity reactions, anaphylaxis or atopy
• Diabetes mellitus, severe cardiopulmonary disorders, history of malignancy in the past 5 years
• Active or passive vaccination within 2 months prior to enrolment, and concomitant vaccination throughout the study period
• Pregnancy or lactation
• Unreliable contraception
• Alcohol consumption
• Drug abuse or addiction within 12 months prior to inclusion
• Participation in a methadone program
• Participation in another study within 1 month prior to enrolment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IC41-C-01/02	IC41	peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
IC41-G-01/02	IC41	peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
IC41-B-01/02	IC41	peptide dose 0.00 mg, polyarginine dose 2.00 mg
IC41-K-01/02	IC41	peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
IC41-H-01/02	IC41	peptide dose: 2.50 mg, polyarginine dose: 2.00 mg

Primary Outcome Measures

Name	Time	Method
Immunological assays	study duration

Secondary Outcome Measures

Name	Time	Method
Safety	study duration